Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Idiopathic Parkinson’s disease ups risk of overactive bladder

12 Mar 2018

Patients with idiopathic Parkinson’s disease (IPD) appear to be at a higher risk of overactive bladder (OAB), a recent study has shown.

Accessing the National Health Insurance Research Database of Taiwan, the researchers identified 4,571 IPD patients and 18,255 non-IPD controls, in whom the occurrence of OAB was evaluated. Cox proportional hazard regression models were used to assess the risk of OAB.

In the IPD cohort, the incidence rate of OAB was calculated to be 14.5 per 10,000 person-years, higher than the 6.37 per 10,00 person-years in the control group. The risk of OAB was significantly higher in the IPD group (hazard ratio [HR], 2.31; 95 percent CI, 1.51–3.52; p<0.001).

The risk elevation remained statistically significant even after multivariate adjustments (HR, 2.30; 1.51–3.51; p<0.001).

When stratifying patients according to comorbidities, the researchers showed that the risk of OAB was significantly elevated in IPD patients with benign prostate hyperplasia (HR, 2.94; 1.66–5.18; p<0.001) and stress incontinence (HR, 3.44; 1.09–10.9; p<0.05).

Kaplan-Meier curves were constructed to determine the cumulative incidence of OAB in both cohorts. The results were significantly higher in the IPD group than in the control cohort after 12 years of follow-up (p<0.001).

The present study shows that there is a correlation between higher OAB risk and IPD. Future studies should then focus on establishing a causal link between the two, according to the researchers.

Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.